Interferon News and Research

RSS

New hope for people with hepatitis C

University of New South Wales (UNSW) researchers are running two new studies on hepatitis C, which could revolutionise treatment for the virus.

22 May 2005

Intralesional immunotherapy for common warts is effective and safe

Injection of skin test antigens (preparations used in skin tests for immunity) into warts appears to stimulate the immune system and successfully treat the injected wart and also helps to treat distant non-injected warts, according to a study in the May issue of Archives of Dermatology.

16 May 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Milk thistle not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease

While some studies found that liver-related mortality may be significantly reduced in patients treated with milk thistle, these findings were not duplicated in the higher quality clinical trials.

2 May 2005

Small number of genes can predict response to chronic hepatitis C therapy

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments.

2 May 2005

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

Dose-limiting anemia can be a prominent adverse event of therapy with pegylated interferon and ribavirin. This dose-ranging study examined whether viramidine, a liver-targeting prodrug of ribavirin, may be a safer alternative when used in combination with pegylated interferon alfa-2a/ PEG-IFN (Pegasys).

23 Apr 2005

Asthmatics naturally deficient in antiviral immunity

Asthmatics produce lower levels of a type of immune cell protein needed to fight off infection from colds and other viruses, scientists have discovered.

6 Apr 2005

New weapon for asthmatics to combat winter asthma attacks

A British team from the University of Southampton, led by the world-acknowledged asthma experts, Professor Stephen Holgate and Professor Donna Davies, has identified a therapy used to treat multiple sclerosis (MS) as a potential novel treatment to reduce asthma attacks caused by the common cold virus.

23 Mar 2005

Why respiratory viral infections are often more severe in people with asthma

Lung cells from asthma sufferers fail to invoke critical anti-viral defenses when infected with the common cold virus, according to a study in the March 21 issue of The Journal of Experimental Medicine. These results could help explain why respiratory viral infections are often more severe in people with asthma and how infection can trigger asthma attacks.

21 Mar 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Medical House signs 10 year license and supply agreement with BioPartners GmbH

The Medical House, orthopaedic devices and drug delivery company and BioPartners GmbH the global biopharmaceuticals company are pleased to announce a 10 year agreement for license and supply of The Medical House's GH1 reusable, spring-powered, needle-free delivery system for the delivery of BioPartners’ human growth hormone product, Valtropin.

22 Feb 2005

Vaccine that boosts the immune response could improve the effect of conventional treatment for patients with chronic myeloid leukaemia

CML is caused by the breakage and swapping of chromosomes 9 and 22, which results in a shortened chromosome called the Philadelphia chromosome. Cells with the abnormal chromosome make a protein that encourages aberrant growth and division. Patients with CML can be treated with a drug called imatinib or interferon alfa.

20 Feb 2005

Studies reveal methods viruses use to sidestep immune system

A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.

17 Feb 2005

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

InterMune, Inc. today announced that CHEST, the journal of the American College of Chest Physicians, published an important analysis of variables that measure clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), a deadly and debilitating lung disease.

10 Jan 2005

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Key molecule helps identify renal cell carcinoma

Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.

30 Nov 2004

Interferon News and Research

New hope for people with hepatitis C

Intralesional immunotherapy for common warts is effective and safe

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Milk thistle not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease

Small number of genes can predict response to chronic hepatitis C therapy

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

Asthmatics naturally deficient in antiviral immunity

New weapon for asthmatics to combat winter asthma attacks

Why respiratory viral infections are often more severe in people with asthma

European approval of Pegasys for the treatment of chronic hepatitis B

Medical House signs 10 year license and supply agreement with BioPartners GmbH

Vaccine that boosts the immune response could improve the effect of conventional treatment for patients with chronic myeloid leukaemia

Studies reveal methods viruses use to sidestep immune system

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Key molecule helps identify renal cell carcinoma

MedImmune and Medarex have announced a collaboration to develop antibodies

FDA approval of Tysabri, for the treatment of multiple sclerosis

Eisai In-licenses Anti-hepatitis B Agent clevudine From Bukwang Pharm

Cellular vehicle delivers drugs directly into cancer cells

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News